A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls
James H McMahon, Jennifer M Zerbato, Jillian SY Lau, Jaclyn L Lange, Michael Roche, Carolin Tumpach, Ashanti Dantanarayana, Ajantha Rhodes, Judy Chang, Thomas A Rasmussen, Charlene A Mackenzie, Karen Alt, Michelle Hagenauer, Janine Roney, Jessica O'Bryan, Alexandra Carey, Richard McIntyre, Paul Beech, Graeme J O'Keefe, Christian W Wichmann Show all
EBIOMEDICINE | ELSEVIER | Published : 2021
BACKGROUND: A research priority in finding a cure for HIV is to establish methods to accurately locate and quantify where and how HIV persists in people living with HIV (PLWH) receiving suppressive antiretroviral therapy (ART). Infusing copper-64 (64Cu) radiolabelled broadly neutralising antibodies targeting HIV envelope (Env) with CT scan and positron emission tomography (PET) identified HIV Env in tissues in SIV infected non-human primates . We aimed to determine if a similar approach was effective in people living with HIV (PLWH). METHODS: Unmodified 3BNC117 was compared with 3BNC117 bound to the chelator MeCOSar and 64Cu (64Cu-3BNC117) in vitro to assess binding and neutralization. In a ..View full abstract
Awarded by Division of AIDS, National Institute of Allergy and Infectious Disease, US National Institutes of Health
Funded by the Alfred Foundation, The Australian Centre for HIV and Hepatitis Virology Research with additional support from the Division of AIDS, National Institute of Allergy and Infectious Disease, US National Institutes of Health (USAI126611) . JHM and SRL are supported by the Australian National Health and Medical Research Council.